FDA Clears AI Software to Enhance CCTA Detection of Coronary Artery Disease
Through AI-powered assessment of coronary computed tomography angiography (CCTA) scans, the CaRi-Plaque software may provide improved clarity on the development of coronary plaques and luminal stenosis.
Offering the promise of improved insights into coronary plaques and luminal stenosis, the artificial intelligence (AI)-enabled CaRi-Plaque software has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Through evaluation of coronary computed tomography angiography (CCTA) scans, reports generated with the CaRi-Plaque software provide actionable insights on plaque burden, total plaque volume, maximum stenosis, calcified plaque volume and other quantitative measures for coronary vessels, according to Caristo Diagnostics, the developer of CaRi-Plaque.
Offering quantitative insights into the extent and severity of coronary plaque and luminal stenosis based on AI assessment of coronary computed tomography angiography (CCTA) scans, the CaRi-Plaque software has garnered 510(k) clearance from the Food and Drug Administration (FDA). (Image courtesy of Caristo Diagnostics.)
By ascertaining the extent and severity of coronary plaque and luminal stenosis, Caristo Diagnostics said the CaRi-Plaque software may facilitate earlier detection of coronary artery disease (CAD) in high-risk patients.
"We stand on the brink of revolution in the prevention and treatment of coronary disease, thanks to Caristo's ability to analyze plaque and inflammation on coronary CT scans," said Stephen A. Bloom, M.D., a cardiologist and director of advance imaging at Midwest Heart & Vascular Specialists in Kansas City. "This advancement enables us to diagnose early stages of coronary disease, even before a coronary CT calcium score becomes positive, allowing for earlier intervention and treatment.”
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
